Non-Hodgkin Lymphoma

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

The combination of the investigative PD-1 inhibitor camrelizumab plus the antiangiogenic agent apatinib led to early signals of clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma, warranting further study.

A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.